Femasys Inc. (FEMY)
NASDAQ: FEMY · IEX Real-Time Price · USD
1.270
-0.020 (-1.55%)
At close: May 17, 2024, 4:00 PM
1.300
+0.030 (2.36%)
After-hours: May 17, 2024, 7:17 PM EDT
Femasys Revenue
Femasys had revenue of $1.05M in the twelve months ending March 31, 2024, down -11.00% year-over-year. Revenue in the quarter ending March 31, 2024 was $271.14K, a -7.77% decrease year-over-year. In the year 2023, Femasys had annual revenue of $1.07M, a decrease of -11.13%.
Revenue (ttm)
$1.05M
Revenue Growth
-11.00%
P/S Ratio
27.11
Revenue / Employee
$32,785
Employees
32
Market Cap
28.44M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.07M | -134.25K | -11.13% |
Dec 31, 2022 | 1.21M | 26.53K | 2.25% |
Dec 31, 2021 | 1.18M | 141.77K | 13.66% |
Dec 31, 2020 | 1.04M | 108.85K | 11.72% |
Dec 31, 2019 | 929.06K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Retractable Technologies | 40.20M |
Spectral AI | 19.30M |
ImmunoPrecise Antibodies | 17.67M |
DURECT | 8.32M |
bioAffinity Technologies | 4.94M |
NeuroOne Medical Technologies | 3.73M |
Singular Genomics Systems | 2.49M |
FEMY News
- 1 day ago - Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative - GlobeNewsWire
- 2 days ago - Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council - GlobeNewsWire
- 9 days ago - Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update - GlobeNewsWire
- 11 days ago - Femasys Expands Commercial Management Team with Addition of Experienced New Hires - GlobeNewsWire
- 4 weeks ago - Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives - GlobeNewsWire
- 7 weeks ago - Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape - GlobeNewsWire
- 2 months ago - Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility - GlobeNewsWire